- Home
- RMCF vs CERO Comparison
RMCF vs CERO Comparison
Compare RMCF & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCF
- CERO
- Stock Information
- Founded
- RMCF 1981
- CERO 2017
- Country
- RMCF United States
- CERO United States
- Employees
- RMCF N/A
- CERO N/A
- Industry
- RMCF Specialty Foods
- CERO
- Sector
- RMCF Consumer Staples
- CERO
- Exchange
- RMCF Nasdaq
- CERO Nasdaq
- Market Cap
- RMCF 11.6M
- CERO 9.6M
- IPO Year
- RMCF N/A
- CERO N/A
- Fundamental
- Price
- RMCF $1.48
- CERO $8.25
- Analyst Decision
- RMCF
- CERO Strong Buy
- Analyst Count
- RMCF 0
- CERO 2
- Target Price
- RMCF N/A
- CERO $45.00
- AVG Volume (30 Days)
- RMCF 22.7K
- CERO 41.3K
- Earning Date
- RMCF 10-14-2025
- CERO 08-22-2025
- Dividend Yield
- RMCF N/A
- CERO N/A
- EPS Growth
- RMCF N/A
- CERO N/A
- EPS
- RMCF N/A
- CERO N/A
- Revenue
- RMCF $29,545,000.00
- CERO N/A
- Revenue This Year
- RMCF N/A
- CERO N/A
- Revenue Next Year
- RMCF N/A
- CERO N/A
- P/E Ratio
- RMCF N/A
- CERO N/A
- Revenue Growth
- RMCF 5.81
- CERO N/A
- 52 Week Low
- RMCF $1.12
- CERO $6.71
- 52 Week High
- RMCF $3.49
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- RMCF 42.85
- CERO 49.24
- Support Level
- RMCF $1.39
- CERO $8.07
- Resistance Level
- RMCF $1.53
- CERO $8.90
- Average True Range (ATR)
- RMCF 0.10
- CERO 0.40
- MACD
- RMCF -0.01
- CERO 0.11
- Stochastic Oscillator
- RMCF 33.48
- CERO 59.38
About RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.